Neurological Therapeutics
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
 
Migraine therapy from the pathogenesis of calcitonin gene–related peptide (CGRP)
Kazumasa Saigoh
Author information
JOURNAL FREE ACCESS

2023 Volume 40 Issue 4 Pages 550-554

Details
Abstract

Calcitonin gene–related peptide (CGRP) is a 37–amino acid peptide primarily located in C and A delta sensory fibers of sensory nerves. These fibers are widely distributed in both central and peripheral perivascular areas and are believed to play a role in nociception by releasing CGRP from sensory nerves. Additionally, they are involved in the stimulation function of peripheral vascular smooth muscle cells and vascular endothelial cells through the descending transmission of CGRP from sensory nerve endings. The vasodilatory effect of CGRP release from trigeminal nerve endings on dural blood vessels is considered a critical pathway related to the pathogenesis of migraine. Based on these findings, a series of anti–CGRP antibody drugs targeting CGRP were launched in 2021. This overview of the pathophysiology of migraine provides a perspective for understanding the mechanism of action of these anti–CGRP antibody drugs.

Content from these authors
© 2023 Japanese Society of Neurological Therapeutics
Previous article Next article
feedback
Top